Sei Investments Co. Has $14.26 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)

Sei Investments Co. raised its stake in shares of Veracyte, Inc. (NASDAQ:VCYT) by 33.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 360,106 shares of the biotechnology company’s stock after purchasing an additional 90,863 shares during the quarter. Sei Investments Co. owned 0.46% of Veracyte worth $14,260,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. American Century Companies Inc. raised its holdings in Veracyte by 66.8% in the 4th quarter. American Century Companies Inc. now owns 11,885 shares of the biotechnology company’s stock valued at $471,000 after acquiring an additional 4,761 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Veracyte by 329.0% during the fourth quarter. Teacher Retirement System of Texas now owns 66,974 shares of the biotechnology company’s stock valued at $2,652,000 after purchasing an additional 51,362 shares during the period. Harvest Fund Management Co. Ltd bought a new position in Veracyte in the fourth quarter worth $468,000. Xponance Inc. acquired a new stake in Veracyte during the fourth quarter worth $257,000. Finally, Parallel Advisors LLC increased its holdings in Veracyte by 6,108.0% in the 4th quarter. Parallel Advisors LLC now owns 8,567 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 8,429 shares during the period.

Insider Activity at Veracyte

In other Veracyte news, Director Karin Eastham sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $40.30, for a total transaction of $403,000.00. Following the transaction, the director now directly owns 18,497 shares in the company, valued at approximately $745,429.10. This represents a 35.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on VCYT. Needham & Company LLC restated a “buy” rating and set a $51.00 price target on shares of Veracyte in a research note on Tuesday, February 25th. Craig Hallum assumed coverage on Veracyte in a research note on Thursday, March 20th. They issued a “buy” rating and a $45.00 price target on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $37.00 price objective (down from $38.00) on shares of Veracyte in a research note on Thursday, December 5th. UBS Group boosted their target price on shares of Veracyte from $46.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Guggenheim restated a “buy” rating and issued a $45.00 price target on shares of Veracyte in a research report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.40.

Veracyte Trading Down 3.2 %

Shares of NASDAQ VCYT opened at $30.12 on Friday. Veracyte, Inc. has a 1-year low of $18.61 and a 1-year high of $47.32. The company has a 50-day moving average of $37.57 and a two-hundred day moving average of $37.69. The company has a market cap of $2.35 billion, a PE ratio of -200.80 and a beta of 1.80.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.07. The firm had revenue of $118.63 million during the quarter, compared to analysts’ expectations of $110.73 million. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. During the same quarter in the previous year, the company posted ($0.39) EPS. As a group, equities research analysts forecast that Veracyte, Inc. will post 0.68 earnings per share for the current year.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.